Immunovant, Inc. Units
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch IMVTU and buy or sell other stocks, options, and ETFs commission-free!About IMVTU
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor.
CEOPeter Salzmann, MD, MBA
CEOPeter Salzmann, MD, MBA
Employees164
Employees164
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2018
Founded2018
Employees164
Employees164
IMVTU Key Statistics
Market cap4.39B
Market cap4.39B
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume183.20
Average volume183.20
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$33.30
52 Week high$33.30
52 Week low$10.32
52 Week low$10.32